Shubham Pant, MD, discusses the expanding pipeline of RAS-directed agents beyond daraxonrasib for patients with pancreatic cancer.
Shubham Pant, MD, MBBS
Advertisement
Shubham Pant, MD, is a professor in the Department of Gastrointestinal (GI) Medical Oncology with a joint appointment in the Department of Investigational Cancer Therapeutics (Phase I Center) at the UT MD Anderson Cancer Center.
Articles by Shubham Pant, MD, MBBS
Dr Shubham Pant outlines what's next for daraxonrasib in pancreatic cancer, including the RASolute 303 and RASolute 304 trials.
Shubham Pant, MD, MBBS, reviews the common adverse effects of daraxonrasib and the prophylactic strategies his team uses to manage them in pancreatic cancer.
Shubham Pant, MD, MBBS, explains the significance of the FDA approval of daraxonrasib for mPDAC.
Dr Pant highlights phase 3 data showing oral daraxonrasib nearly doubles overall survival vs chemotherapy in metastatic pancreatic cancer.
Discover the latest advancements in pancreatic cancer treatment, including targeted therapies and next-generation sequencing, transforming patient care and outcomes.
Shubham Pant, MD, discusses background on zanidatamab and findings from the HERIZON-BTC-01 trial of the agent for HER2-positive biliary tract cancer treatment.
Shubham Pant, MD, discusses the ESPAC-5F trial methods and efficacy in patients with pancreatic cancer.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Insurance Delays and Travel Strain CAR T Referral in Early Relapsed Myeloma
2
NCCN Guidelines Add Cosibelimab for Locally Advanced CSCC
3
Real-World Data for Darolutamide vs Abiraterone Triplet Therapy in mHSPC
4
Oncologists Debate Role of On-Body Injector for Transplant-Ineligible Myeloma
5